CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and
biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane
Antigen expressing tumors, such as has been described for some renal cell carcinoma tumors.